Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

Matthew G. Soars, Ken Grime, Joanne L. Sproston, Peter J. H. Webborn and Robert J. Riley
Drug Metabolism and Disposition June 2007, 35 (6) 859-865; DOI: https://doi.org/10.1124/dmd.106.014464
Matthew G. Soars
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Grime
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne L. Sproston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. H. Webborn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Riley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The wealth of information that has emerged in recent years detailing the substrate specificity of hepatic transporters necessitates an investigation into their potential role in drug elimination. Therefore, an assay in which the loss of parent compound from the incubation medium into hepatocytes (“media loss” assay) was developed to assess the impact of hepatic uptake on unbound drug intrinsic clearance in vivo (CLint ub in vivo). Studies using conventional hepatocyte incubations for a subset of 36 AstraZeneca new chemical entities (NCEs) resulted in a poor projection of CLint ub in vivo (r2 = 0.25, p = 0.002, average fold error = 57). This significant underestimation of CLint ub in vivo suggested that metabolism was not the dominant clearance mechanism for the majority of compounds examined. However, CLint ub in vivo was described well for this dataset using an initial compound “disappearance” CLint obtained from media loss assays (r2 = 0.72, p = 6.3 × 10-11, average fold error = 3). Subsequent studies, using this method for the same 36 NCEs, suggested that the active uptake into human hepatocytes was generally slower (3-fold on average) than that observed with rat hepatocytes. The accurate prediction of human CLint ub in vivo (within 4-fold) for the marketed drug transporter substrates montelukast, bosentan, atorvastatin, and pravastatin confirmed further the utility of this assay. This work has described a simple method, amenable for use within a drug discovery setting, for predicting the in vivo clearance of drugs with significant hepatic uptake.

Footnotes

  • doi:10.1124/dmd.106.014464.

  • ABBREVIATIONS: DMPK, drug metabolism and pharmacokinetics; OATP, organic anion transporting polypeptide; NCE, new chemical entity; AZ, AstraZeneca; BSA, bovine serum albumin; CLint, intrinsic clearance; AUC0-∞, area under the drug concentration-time curve from time zero to a point where the drug concentration is zero (extrapolated from the final two time points); CLint ub in vitro, unbound drug intrinsic clearance in vitro; CLint ub in vivo, unbound drug intrinsic clearance in vivo; fuinc, fraction of drug unbound in the hepatocyte incubation; fmedium, fraction of drug in the incubation medium; PgP, P-glycoprotein.

    • Received December 20, 2006.
    • Accepted March 1, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 35 (6)
Drug Metabolism and Disposition
Vol. 35, Issue 6
1 Jun 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

Matthew G. Soars, Ken Grime, Joanne L. Sproston, Peter J. H. Webborn and Robert J. Riley
Drug Metabolism and Disposition June 1, 2007, 35 (6) 859-865; DOI: https://doi.org/10.1124/dmd.106.014464

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

Matthew G. Soars, Ken Grime, Joanne L. Sproston, Peter J. H. Webborn and Robert J. Riley
Drug Metabolism and Disposition June 1, 2007, 35 (6) 859-865; DOI: https://doi.org/10.1124/dmd.106.014464
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
  • Biotransformation of Trastuzumab and Pertuzumab
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics